Huge improvements in treatments for type 2 diabetes are outlined in recent diabetes guidelines. Get the upshot on best evidence from leading experts Drs Silvio Inzucchi and Rita Kalyani.

Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963267). The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals.

Resources

Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022 https://diabetesjournals.org/care/article/45/Supplement_1/S125/138908/9-Pharmacologic-Approaches-to-Glycemic-Treatment

Guidance for Industry: Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes https://www.fda.gov/media/71297/download

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/nejmoa1504720

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/nejmoa1603827

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.042007

Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31149-3/fulltext

Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/NEJMoa1607141

SGLT2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-analysis of the EMPEROR-Reduced and DAPA-HF Trials https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31824-9/fulltext

The SGLT2 Inhibitor Dapagliflozin in Heart Failure With Preserved Ejection Fraction: A Multicenter Randomized Trial https://www.nature.com/articles/s41591-021-01536-x

A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial) (REMODEL) https://clinicaltrials.gov/ct2/show/NCT04865770